In short, through this study, we found that vitamin D treatment of RA may occur through antifolate resistance, osteoclast differentiation, and the NF-κB signaling pathway, acting on ALB, TNF, CASP3, and TP53 targets. The gene discussed is TP53; the disease is rheumatoid arthritis.